Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Is Tau Aggregation Toxic or Protective?

(2017) Erin E. Congdon et al.   JOURNAL OF ALZHEIMERS DISEASE

Tau Aggregates: Toxic, Inert, or Protective Species?

(2017) Alexis Bretteville et al.   JOURNAL OF ALZHEIMERS DISEASE

Chaperone-like Antibodies Targeting Misfolded Tau Protein: New Vistas in the Immunotherapy of Neurodegenerative Foldopathies

(2017) Norbert Zilka et al.   JOURNAL OF ALZHEIMERS DISEASE

Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β

(2017) Rudy J. Castellani et al.   JOURNAL OF ALZHEIMERS DISEASE

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

(2017) Noel G. Faux et al.   JOURNAL OF ALZHEIMERS DISEASE

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

(2011) Bruno P Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid

(2010) V. Frisardi et al.   Current Alzheimer Research

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

(2010) Moran Boimel et al.   EXPERIMENTAL NEUROLOGY

Bapineuzumab

(2010) Geoffrey A Kerchner et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease

(2010) Francesco Panza et al.   Immunotherapy

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment

(2009) Ronald B. DeMattos et al.   Alzheimers & Dementia

Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy

(2009) Michal Novak   Alzheimers & Dementia

Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy

(2009) Eva Kontsekova et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

(2009) Rakez Kayed et al.   CURRENT OPINION IN IMMUNOLOGY

Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease

(2009) Francesco Panza et al.   DRUGS & AGING

Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?

(2009) Gregory A Jicha   EXPERT OPINION ON BIOLOGICAL THERAPY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

(2009) M. Britschgi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease

(2008) Eric R. Siemers et al.   Alzheimers & Dementia

Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior

(2008) Dennis J. Selkoe   BEHAVIOURAL BRAIN RESEARCH

Aging and Infectious Diseases: Workshop on HIV Infection and Aging: What Is Known and Future Research Directions

(2008) Rita B. Effros et al.   CLINICAL INFECTIOUS DISEASES

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Amyloid-β immunisation for Alzheimer's disease

(2008) Thomas Wisniewski et al.   LANCET NEUROLOGY

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse

(2008) Peter Seubert et al.   Neurodegenerative Diseases

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

(2008) Scott A. Small et al.   NEURON

Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools

(2007) Peter Lichtlen et al.   JOURNAL OF NEUROCHEMISTRY